title: The new prophylactic strategy for colon cancer in inflammatory bowel disease by modulating microbiota.
abstract: It is well understood that intestinal microbiota play an important role in the pathogenesis of inflammatory bowel disease (IBD). In addition, IBD patients are well known to have a higher risk of developing colon cancer due to chronic inflammation. Recent evidence suggests that manipulation of microbiota improves the clinical outcome of patients with IBD and may reduce onset of colon cancer without obvious toxicity. This review summarizes the current experimental and clinical knowledge about the role of intestinal microbiota in IBD and colon cancer, and the nutraceutical therapy for colon cancer.
authors.affiliation: Strategic Research and Development Department Kirin Holdings Co., Ltd., Chuo-ku, Tokyo, Japan. kanauchio@kirin,co.jp
authors.forename: Osamu
authors.initials: O
authors.lastname: Kanauchi
authors.forename: Keiichi
authors.initials: K
authors.lastname: Mitsuyama
authors.forename: Akira
authors.initials: A
authors.lastname: Andoh
mesh_terms: D003110:Colonic Neoplasms / Q000382:microbiology / Q000517:prevention & control*; D019587:Dietary Supplements; D019317:Evidence-Based Medicine; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D007413:Intestinal Mucosa / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D054892:Metagenome / Q000187:drug effects*